HRO761

Novartis'HRO761 is an oral allosteric inhibitor targeting WRN helicase, aimed at treating microsatellite instability (MSI) or deficient mismatch repair (dMMR) tumors. WRN has emerged as a critical synthetic lethal target in MSI cancers, which are common in colorectal, gastric, endometrial, and ovarian cancers. Although MSI cancers show a high response rate to immune checkpoint inhibitors, many patients develop resistance. By acting on WRN, HRO761 may be able to stop the growth of the cancer.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.